These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 32139006)
21. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W; PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956 [TBL] [Abstract][Full Text] [Related]
22. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. McCarthy PL J Natl Compr Canc Netw; 2013 Jan; 11(1):35-42. PubMed ID: 23307979 [TBL] [Abstract][Full Text] [Related]
23. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M; Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443 [TBL] [Abstract][Full Text] [Related]
29. Lenalidomide maintenance in Myeloma - a goldilocks problem? Ng Liet Hing M; Khot A Leuk Lymphoma; 2023 Oct; 64(10):1611-1614. PubMed ID: 37671741 [No Abstract] [Full Text] [Related]
30. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Mohan M; Janz S; Brazauskas R; Dwinell MB; Teng BQ; Yun G; Dong J; Pasquini MC; Giralt S; Landau H; Stadtmauer E; Krishnan A; D'Souza A Bone Marrow Transplant; 2023 Aug; 58(8):953-955. PubMed ID: 37149674 [No Abstract] [Full Text] [Related]
31. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Manda S; Yimer HA; Noga SJ; Girnius S; Yasenchak CA; Charu V; Lyons R; Aiello J; Bogard K; Ferrari RH; Cherepanov D; Demers B; Lu V; Whidden P; Kambhampati S; Birhiray RE; Jhangiani HS; Boccia R; Rifkin RM Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e910-e925. PubMed ID: 32912820 [TBL] [Abstract][Full Text] [Related]
32. Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Zweegman S; Stege CAM; Haukas E; Schjesvold FH; Levin MD; Waage A; Leys RBL; Klein SK; Szatkowski D; Axelsson P; Hieu Do T; Knut-Bojanowska D; van der Spek E; Svirskaite A; Klostergaard A; Salomo M; Blimark C; Ypma PF; Mellqvist UH; Poddighe PJ; Stevens-Kroef M; van de Donk NWCJ; Sonneveld P; Hansson M; van der Holt B; Abildgaard N Haematologica; 2020 Dec; 105(12):2879-2882. PubMed ID: 33256392 [No Abstract] [Full Text] [Related]
34. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870 [TBL] [Abstract][Full Text] [Related]
35. Maintenance therapy for multiple myeloma. McCarthy PL; Palumbo A Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886 [TBL] [Abstract][Full Text] [Related]
36. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187 [TBL] [Abstract][Full Text] [Related]
37. Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. Rath C; Yoo C; Cheplowitz H; Lo M; Young R; Guglielmo J; Saunders IM; Banerjee R; Young R; Kumar A; Chung A; Rosenberg AS; Costello C; Fine J; Wilson M; Patel N; Banez MT J Oncol Pharm Pract; 2023 Oct; 29(7):1715-1724. PubMed ID: 36731514 [TBL] [Abstract][Full Text] [Related]
38. The role of maintenance therapy in multiple myeloma. Lipe B; Vukas R; Mikhael J Blood Cancer J; 2016 Oct; 6(10):e485. PubMed ID: 27768093 [TBL] [Abstract][Full Text] [Related]
40. The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. Kesireddy M; Holstein SA Expert Rev Clin Pharmacol; 2022 Jan; 15(1):19-31. PubMed ID: 35061547 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]